In some cases of TSH-secreting pituitary tumors, a drug called octreotide can normalize thyroid hormone levels before surgery, offering a way to prepare patients for safer operation.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether octreotide is more effective than placebo or no treatment in normalizing thyroid function in patients with TSHomas prior to surgery.
A double-blind, placebo-controlled RCT of 40+ patients with confirmed TSHomas, randomized to octreotide 100 mcg three times daily or placebo for 8 weeks, with primary outcome of free T4 normalization and secondary outcomes of TSH and alpha-subunit reduction.
The rate of biochemical normalization with octreotide in a real-world cohort of TSHoma patients before surgery.
A prospective cohort study of 30+ patients with TSHomas treated with octreotide (100 mcg TID) for ≥4 weeks prior to surgery, measuring changes in T4, T3, TSH, and alpha-subunit levels to determine response rate.
That octreotide can normalize thyroid function in TSHomas, as observed in this patient.
A case series of 5+ patients with TSHomas treated with octreotide 100 mcg TID, documenting biochemical response before surgery, as presented in this study.